Plant Name: Pueraria montana var. lobata
Taxonomic Information:
Plant ID: NPO8707.1
Plant Latin Name: Pueraria montana var. lobata
Taxonomy Genus: Pueraria
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
132459
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
South Korea; IndiaTraditional Medicine System:
Geographical Distribution:
South Korea; India
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ACHE; | |
| TDP1; BLM; MIF; NOX4; AOX1; | |
| FLT3; EGFR; | |
| CA2; CA1; CA12; CA9; CA14; CA7; CA4; | |
| ESR1; ESR2; | |
| NR1H4; | |
| ESRRB; ESRRA; | |
| ALDH2; | |
| MMP9; MMP12; MMP2; | |
| HIF1A; | |
| LMNA; FABP4; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.745E-13 | 1.267E-09 | BLM, CA1, CA12, CA2, CA4, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, MMP12, MMP2, MMP9, NR1H4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.775E-13 | 2.055E-09 | CA1, CA12, CA14, CA2, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.554E-11 | 5.640E-08 | CA1, CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 2.030E-07 | 2.105E-04 | ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 1.415E-06 | 1.062E-03 | ACHE, EGFR, HIF1A, MIF, MMP12, NR1H4 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.591E-06 | 1.155E-03 | ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.332E-06 | 1.539E-03 | ESR1, ESR2 |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 3.786E-06 | 2.290E-03 | EGFR, ESRRB, HIF1A |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 4.415E-06 | 2.530E-03 | ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 6.837E-06 | 3.539E-03 | ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.989E-06 | 3.539E-03 | CA2, CA7 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 9.188E-06 | 4.086E-03 | HIF1A, MMP12, MMP2, MMP9 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 9.195E-06 | 4.086E-03 | CA2, CA4, CA9, EGFR, TSHR |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.417E-05 | 5.509E-03 | BLM, CYP1B1, EGFR, ESR1, FLT3, NOX4 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.396E-05 | 5.509E-03 | ESR1, ESR2 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.103E-05 | 7.285E-03 | HIF1A, MMP12, MMP2, MMP9 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 2.758E-05 | 8.908E-03 | BLM, EGFR, MMP2, NOX4, NR1H4, TSHR |
| MF | GO:0005488; binding | GO:0003690; double-stranded DNA binding | 2.782E-05 | 8.908E-03 | EGFR, ESR1, ESR2, ESRRA, ESRRB, HIF1A, NR1H4, TDP1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.533E-17 | 1.423E-12 | CA1, CA12, CA14, CA2, CA4, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.545E-16 | 1.437E-14 | CA12, CA1, CA2, CA4, CA7, CA9, CA14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 3.467E-07 | 1.612E-05 | MMP2, ESR1, MMP9, EGFR, ESR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.189E-05 | 3.685E-04 | MMP2, HIF1A, ESR1, MMP9, EGFR |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.898E-05 | 5.810E-04 | ALDH2, AOX1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 3.124E-05 | 5.810E-04 | MMP2, MMP9, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.844E-04 | 3.779E-03 | FLT3, MMP2, HIF1A, MMP9, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.367E-04 | 2.119E-03 | FLT3, HIF1A, EGFR |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 5.396E-04 | 6.273E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; EGFR; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; EGFR; CA9; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; MMP9; EGFR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | EGFR; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ESRRA; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; HIF1A; MMP9; EGFR; MMP2; CA9; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; CA1; |
| NA: NA | GIST | NA | FLT3; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; MMP2; |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; MMP2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; FLT3; EGFR; CA9; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; MIF; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; FLT3; ACHE; HIF1A; MMP9; EGFR; MMP2; CA1; CA9; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ALDH2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; EGFR; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ALDH2; EGFR; |
| C00-D49: Neoplasms | AML | NA | FLT3; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; MIF; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
